Serum and Tissue Accumulation of Advanced Glycation End-Products Correlates with Vascular Changes

Hocine, Aldjia; Belmokhtar, Karim; Bauley, Karine; Jaisson, Stéphane; Gaha, K.; Oubaya, Nadia; Lesaffre, François; Lavaud, Sylvie; Halin, Pascale; Gillery, Philippe; Rieu, Philippe; Touré, Fatouma

doi:10.3747/pdi.2013.00338

Cited by 6 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Groups were comparable for gender, BMI, diabetes, months of PD treatment, dialysate glucose exposure and measured daily peritoneal glucose absorption, and residual renal function. However, we did not formally measure serum AGEs, which are a group of compounds with variable molecular weights, and some studies which have measured low molecular weight AGEs in patients not treated by dialysis have not demonstrated a strong association between some low molecular weight AGEs and SAF, 36 whereas others have shown a positive association in PD patients 24 . Patients using dual chamber low GDP dialysates had significantly slower peritoneal membrane transport, and as such had greater peritoneal ultrafiltration volumes with similar dialysate glucose prescriptions and peritoneal glucose absorption, but had greater ECW/TBW ratios and as such our report may suggest that overall dual chamber low GDP PD dialysates may have some of the benefits of preserving the peritoneal membrane as suggested by other studies.…”

Section: Discussionmentioning

confidence: 98%

“…21,22 Dual chamber low GDP PD dialysates have been shown to lower AGEs associated with a reduction in proinflammatory mediators. 23 A previous study reported that PD patients treated with dual chamber low GDP dialysates had lower tissue AGE deposition, 24,25 although studies have differed as to whether these findings were confounded by other factors. 25 We therefore wished to determine whether dialyzing using dual chamber low GDP dialysates led to a reduction in tissue AGE deposition measuring SAF in a much larger cohort than previously reported.…”

Section: Discussionmentioning

confidence: 99%

“…17 Our study included many more patients, and patients had been treated for a similar time with PD, whereas in the earlier positive report, patients using the standard single chamber dialysates had been treated for a median of 102 months compared to 44 for those using dual chamber low GDP dialysates. 24,25 Note: Data expressed as mean ± standard deviation, and median (inter-quartile range).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids

et al. 2020

View full text Add to dashboard Cite

Dual chamber (DC) peritoneal dialysis (PD) dialysates contain fewer glucose degradation products (GDPs), so potentially reducing advanced glycosylation end products (AGEs), which have been reported to increase inflammation and cardiovascular risk. We wished to determine whether use of DC dialysates resulted in demonstrable patient benefits. Biochemical profiles, body composition, muscle strength, and skin autofluorescence measurements of tissue AGEs (SAF) were compared in patients using DC and standard single chamber dialysates. We studied 263 prevalent PD patients from 2 units, 62.4% male, mean age 61.8 ± 16.1 years, 78 (29.7%) used DC dialysates. DC patients were younger (55.9 ± 16.4 vs. 64.2 ± 15.4 years), and more had lower Davies comorbidity score (median 1 (0‐1) vs. 1 (0, 2)), slower peritoneal transport (D/P creatinine 0.67 ± 0.12 vs. 0.73 ± 0.13), greater extracellular water‐to‐total body water (ECW/TBW) ratio (0.46 ± 0.05 vs. 0.42 ± 0.06), all P < .001, whereas there were no differences in the duration of PD (median (IQR) 19 (8‐32) vs. 14 (8‐23) months), residual renal function (Kt/Vurea 0.71 ± 0.71 vs. 0.87 ± 0.82), urine volume (642 (175‐1200) vs. 648 (300‐1200) mL/day), hand grip strength (26.9 ± 10.5 vs. 24.9 ± 10.7 kg), C‐reactive protein (4(1‐10) vs. 4(2‐12) mg/L), and SAF (median 3.60 (3.02, 4.40) vs. 3.50 (3.00, 4.23)) AU. In our cross‐sectional observational study, we were not able to show a demonstrable advantage for using low GDP dialysates over conventional glucose dialysates, in terms of biochemical profiles, residual renal function, muscle strength, or tissue AGE deposition. More patients using low GDP dialysates were slower peritoneal transporters with higher ECW/TBW ratios.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Glycation is defined as the binding of sugar carbonyl groups to free amino groups of proteins, leading to the generation of AGEs after exposure to irreversible oxidative reactions [60]. Several studies have demonstrated a significant association between AGE and arterial stiffness in ESRD patients [64][65][66]. AGEs have also been involved in uraemic vasculopathy.…”

Section: Effect Of Advanced Glycation End Products (Ages) On Vsmc Functionsmentioning

confidence: 99%

Arterial Remodelling in Chronic Kidney Disease: Impact of Uraemic Toxins and New Pharmacological Approaches

Foudi

Briet

Garnier

2021

JCM

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a major public health concern that affects around 10 percent of the world’s population. The severity of CKD is mainly due to the high prevalence of cardiovascular (CV) complications in this population. The aim of this review is to describe the arterial remodelling associated with CKD, to provide a quick overview of the mechanisms involved and to review the recent pharmacological approaches aimed at improving vascular health in CKD. CKD patients are exposed to metabolic and haemodynamic disorders that may affect the CV system. Large artery functional and geometric abnormalities have been well documented in CKD patients and are associated with an increase in arterial stiffness and a maladaptive remodelling. Uraemic toxins, such as indoxyl sulphate, p-cresyl sulphate, protein carbamylation and advanced glycation products, exert various effects on vascular smooth muscle cell functions. The low-grade inflammation associated with CKD may also affect arterial wall composition and remodelling. It is worth noting that the CV risk for CKD patients remains high despite the pharmacological control of traditional CV risk factors, suggesting the need for innovative therapeutic strategies. An interventional study targeting the NLRP3 inflammasome has provided some interesting preliminary results that need to be confirmed, especially in terms of safety.

show abstract

AgeR deletion decreases soluble fms-like tyrosine kinase 1 production and improves post-ischemic angiogenesis in uremic mice

Dupont¹,

Al-Rifai²,

Poitevin³

et al. 2020

Angiogenesis

View full text Add to dashboard Cite

Serum and Tissue Accumulation of Advanced Glycation End-Products Correlates with Vascular Changes

Cited by 6 publications

References 7 publications

Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids

Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids

Arterial Remodelling in Chronic Kidney Disease: Impact of Uraemic Toxins and New Pharmacological Approaches

AgeR deletion decreases soluble fms-like tyrosine kinase 1 production and improves post-ischemic angiogenesis in uremic mice

Contact Info

Product

Resources

About